Intrinsic Value of S&P & Nasdaq Contact Us

Hypera S.A. HYPMY OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • BR • USD

SharesGrow Score
60/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Hypera S.A. (HYPMY) trades at a trailing P/E of 2.5. Trailing earnings yield is 40.49%.

Criteria proven by this page:

  • VALUE (100/100, Pass) — P/E is below market average (2.5); earnings yield beats bond yields (40.49%).
  • Trailing Earnings Yield 40.49% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.

Overall SharesGrow Score: 60/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
60/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
20/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
65/100
→ Income
GROWTH
30/100
→ Income
INCOME
70/100
→ Income

Valuation Snapshot — HYPMY

Valuation Multiples
P/E (TTM)2.5
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.39
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.89
Book Value / Share$0.00
Revenue / Share$12.10
FCF / Share$0.00
Yields & Fair Value
Earnings Yield40.49%
Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $1.84 $3.29B $1.18B 35.8%
2017 $1.52 $3.64B $964.94M 26.5%
2018 $1.77 $3.72B $1.13B 30.3%
2019 $1.82 $3.29B $1.16B 35.3%
2020 $2.03 $4.09B $1.3B 31.7%
2021 $2.08 $5.94B $1.33B 22.4%
2022 $2.65 $7.55B $1.7B 22.5%
2023 $2.58 $7.91B $1.65B 20.8%
2024 $2.10 $7.44B $1.34B 18%
2025 $1.89 $7.7B $1.2B 15.5%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message